Compare Fiverr International Ltd (FVRR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Fiverr International Ltd trades at $11.86 (market cap $404.45M), while Regeneron Pharmaceuticals Inc trades at $677.59 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 172.2× Fiverr International Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | REGN | |
|---|---|---|
Market Cap | $404.45M | $69.66B |
Sector | Industrials | Health |
52-Week High | $26.67 | $812.27 |
52-Week Low | $9.62 | $542.52 |
Enterprise Value | $135.05M | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.82, up 6.78% in the last session, showing strong momentum despite recent volatility. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, revenue grew to $430.91M in 2025 with improving net margins, while valuation ratios like P/E of 14.61 and P/S of 0.97 suggest potential undervaluation. Recent news highlights Fiverr's upcoming Q2 2026 earnings report on July 29, 2026, amid mixed sentiment from financial media.
The outlook for FVRR hinges on execution of its strategic shift and Q2 earnings performance. Opportunities include attractive valuation multiples and operational cash flow growth, but risks involve declining active buyers and ongoing legal investigations. Analyst consensus leans neutral with 41% buy ratings, reflecting cautious optimism pending clearer business traction.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
